Cargando…

Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial

INTRODUCTION: Sonidegib is a Hedgehog pathway inhibitor approved to treat locally advanced basal cell carcinoma and, depending on regulatory approval, metastatic basal cell carcinoma. Results from the BOLT study demonstrated robust efficacy and continued tolerability through 42 months. This analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewis, Karl, Dummer, Reinhard, Farberg, Aaron S., Guminski, Alexander, Squittieri, Nicholas, Migden, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611137/ https://www.ncbi.nlm.nih.gov/pubmed/34669179 http://dx.doi.org/10.1007/s13555-021-00619-4

Ejemplares similares

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
por: Dummer, R., et al.
Publicado: (2019)

Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis
por: Gutzmer, Ralf, et al.
Publicado: (2021)

Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
por: Lear, J.T., et al.
Publicado: (2017)

Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma
por: Dummer, Reinhard, et al.
Publicado: (2020)

Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial
por: Lear, John T, et al.
Publicado: (2020)

Sonidegib improved quality of life in patients with advanced basal cell carcinoma: Results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks
por: Migden, Michael, et al.
Publicado: (2022)

Sonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma
por: Doan, Hung Q, et al.
Publicado: (2016)

Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis
por: Gutzmer, Ralf, et al.
Publicado: (2021)

The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area
por: Villani, Alessia, et al.
Publicado: (2023)

Sonidegib for the Treatment of Advanced Basal Cell Carcinoma
por: Brancaccio, Gabriella, et al.
Publicado: (2020)

Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma
por: Lear, John T., et al.
Publicado: (2021)

Sonidegib: Safety and Efficacy in Treatment of Advanced Basal Cell Carcinoma
por: Villani, Alessia, et al.
Publicado: (2020)

Giant basal cell carcinoma of the vulva successfully treated with Sonidegib
por: Camela, Elisa, et al.
Publicado: (2022)

Sonidegib treatment in patients with locally advanced basal cell carcinoma
por: Villani, Alessia, et al.
Publicado: (2022)

First reported case of concurrent sonidegib and radiotherapy for recurrent, advanced basal cell carcinoma
por: Wang, Kaidi, et al.
Publicado: (2021)

Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma
por: Wahid, Mohd, et al.
Publicado: (2017)

Effective systemic treatment of advanced periocular basal cell carcinoma with sonidegib
por: Rokohl, Alexander C., et al.
Publicado: (2021)

Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas
por: Villani, Alessia, et al.
Publicado: (2022)

Experience with sonidegib in patients with advanced basal cell carcinoma: case reports
por: Puig, Susana, et al.
Publicado: (2022)

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas
por: Jain, Sachin, et al.
Publicado: (2017)

Sonidegib‐induced muscle spasms in the treatment of basal cell carcinoma: Strategies to adopt
por: Villani, Alessia, et al.
Publicado: (2022)

Clinical Clearance Following Improvement of Histologic Subtype of Basal Cell Carcinoma with Sonidegib
por: LEOW, Liang Joo, et al.
Publicado: (2022)

Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma: A Retrospective Study
por: HERMS, Florian, et al.
Publicado: (2022)

A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
por: Odom, Dawn, et al.
Publicado: (2017)

Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma
por: García Ruiz, Antonio J, et al.
Publicado: (2022)

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib
por: Yoon, Jaeyoung, et al.
Publicado: (2017)

Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas
por: Tarantino, Vanessa, et al.
Publicado: (2021)

Clinical clearance of complex basal cell carcinoma in patients receiving sonidegib: A case series
por: Leow, Liang Joo, et al.
Publicado: (2021)

Optimizing the pharmacokinetics of sonidegib in small bowel syndrome and advanced basal cell carcinoma: Our solution
por: Grubbs, Hailey, et al.
Publicado: (2023)

Sonidegib after vismodegib discontinuation in a patient with Gorlin–Goltz syndrome and multiple basal cell carcinomas
por: Piccerillo, Alfredo, et al.
Publicado: (2021)

Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series
por: Wescott, Raquel, et al.
Publicado: (2023)

Tolerance of sonidegib after intolerance of vismodegib—Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome)
por: Venturi, Federico, et al.
Publicado: (2023)

Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice
por: Ruiz-Villaverde, Ricardo, et al.
Publicado: (2023)

Bolt from the blue: Basal ganglion bleed following lightning strike
por: Aggarwal, Ashish, et al.
Publicado: (2011)

Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data
por: Nazzaro, Gianluca, et al.
Publicado: (2023)

Targeted Delivery of 5-Fluorouracil and Sonidegib via Surface-Modified ZIF-8 MOFs for Effective Basal Cell Carcinoma Therapy
por: Padya, Bharath Singh, et al.
Publicado: (2023)

Cdc42 regulates Cdc42EP3 function in cancer-associated fibroblasts
por: Farrugia, Aaron J., et al.
Publicado: (2016)

The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
por: Colombo, Elena, et al.
Publicado: (2023)

Improving the Antitumor Activity and Bioavailability of Sonidegib for the Treatment of Skin Cancer
por: Gamal, Amr, et al.
Publicado: (2021)

Evaluation of Hedgehog Pathway Inhibition on Nevoid Basal Cell Carcinoma Syndrome Fibroblasts and Basal Cell Carcinoma-Associated Fibroblasts: Are Vismodegib and Sonidegib Useful to Target Cancer-Prone Fibroblasts?
por: Eibenschutz, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5hq9cabml1boa03ohqd90jtulj